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Abstract
Background: Modifications of adjuvants that induce cell-mediated over antibody-mediated immunity is desired for
development of vaccines. Nanocapsules have been found to be viable adjuvants and are amenable to engineering for
desired immune responses. We previously showed that natural nanocapsules called vaults can be genetically engineered to
elicit Th1 immunity and protection from a mucosal bacterial infection. The purpose of our study was to characterize
immunity produced in response to OVA within vault nanoparticles and compare it to another nanocarrier.
Methodology and Principal Findings: We characterized immunity resulting from immunization with the model antigen,
ovalbumin (OVA) encased in vault nanocapsules and liposomes. We measured OVA responsive CD8+ and CD4+ memory T
cell responses, cytokine production and antibody titers in vitro and in vivo. We found that immunization with OVA contain in
vaults induced a greater number of anti-OVA CD8+ memory T cells and production of IFNc plus CD4+ memory T cells. Also,
modification of the vault body could change the immune response compared to OVA encased in liposomes.
Conclusions/Significance: These experiments show that vault nanocapsules induced strong anti-OVA CD8+ and CD4+ T cell
memory responses and modest antibody production, which markedly differed from the immune response induced by
liposomes. We also found that the vault nanocapsule could be modified to change antibody isotypes in vivo. Thus it is
possible to create a vault nanocapsule vaccine that can result in the unique combination of immunogen-responsive CD8+
and CD4+ T cell immunity coupled with an IgG1 response for future development of vault nanocapsule-based vaccines
against antigens for human pathogens and cancer.
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Introduction
With ongoing disease threats and the promise of emerging
immunotherapies, demand for new vaccine technologies is
growing. Developing effective and potent vaccines remains one
of the most cost-effective strategies for preventing infectious
diseases and cancers [1,2]. Vaccines containing killed or inacti-
vated intact microbes elicit strong immune responses but also
produce considerable inflammation at the site of vaccination [3–
5]. Furthermore, engineered live vaccines, such as non-replicating
recombinant viruses have been developed and also induce robust
immune responses [6–8]. However, the potential for break-
through replication of live vectors and anti-vector immunity
further discourage the development of live vector vaccines due to
safety concerns [9,10]. To further vaccine development, non-
replicating adjuvants are needed which induce robust immunity
with minimal inflammation.
The immune-promoting activity of any given vaccination
strategy is determined by the presence of the relevant antigenic
components in the vaccine formulation, enhanced by the addition
of suitable adjuvants capable of activating and promoting an
efficient immune response against infectious agents or cancers
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[1,2]. One approach for tailoring vaccines to elicit certain types of
immune responses while avoiding inflammation is to develop
subunit vaccines by combining non-living or synthetic antigens
with adjuvants [9]. This type of vaccine can deliver defined
antigens with reduced inflammatory cytokine production but is
depended on the adjuvant formulation to stimulate cell-mediated
immune responses and protection from infectious challenge or
prevent tumor growth [11,12]. Most licensed vaccines promote
immunity by eliciting humoral immune responses and weak
cellular immune responses. Current efforts are directed to
producing adjuvants which elicit cell-mediated immunity [13,14].
A major limiting factor in the development of subunit vaccines
is engineering immune adjuvants to induce cell-mediated immu-
nity and encourage CD8+ T cell responses through major
histocompatibility complex (MHC) class I presentation (MHC-I,
cross presentation). Previous work has shown that it is difficult to
achieve antigen presentation through MHC-I molecules unless the
antigen is specifically targeted to the MHC-I processing machinery
[15–17]. A wide range of approaches has been explored including
CpG-DNA or toll-like receptor (TLR) ligands, recombinant viral
vectors, fusion with bacterial toxins and others [18,19]. Adjuvants
can also be designed to elicit specific immunity, such as promoting
cellular immunity which is important for protection against many
pathogens [20]. Currently none have been successfully developed
for use in humans.
Nanoparticle pharmaceutical carriers can be engineered to elicit
various types of immunity and are increasingly investigated as
adjuvants for vaccines. Different types of nanocarriers, such as
polymers (polymeric nanoparticles, micelles, or dendrimers), lipids
(liposomes), viruses (viral nanoparticles), and organometallic
compounds (carbon nanotubes) have been employed for immu-
notherapeutic applications [21–23]. We have engineered vaults
using a recombinant technique to function as a nanocarrier.
Natural vaults are barrel-shaped, hollow, 13 mDa ribonucleopro-
tein particles that exist in nearly all eukaryotic cells [24,25]. Their
precise function is unknown but they have been associated with
multidrug resistance, cell signaling, nuclear-cytoplasmic transport
and innate immunity [26]. We have shown that recombinant
vaults can be produced to contain a bacterial antigen and induce
adaptive immune responses and protective immunity following
immunization [27]. In addition, vault nanocapsules can also be
engineered to promote anti-tumor responses [28]. These studies
show that recombinant vault nanocapsules act as adjuvants, are
versatile for eliciting various types of immunity and have
outstanding potential for compound encapsulation, protection,
and delivery.
Figure 1. Analysis of purified recombinant vault particles containing OVA-INT. (A) Representative gel image showing co-purification of the
protein species MVP and OVA-INT. Sucrose gradients of 40% to 60% run in SDS-PAGE (4%–15%). Lane: M: protein molecular weight markers, 40:40%
fractions of sucrose gradient and 45% fractions of sucrose gradient. (B) The gradient fractions were probed with either anti-MVP rabbit polyclonal
antisera or (C) anti-OVA rabbit polyclonal antisera. (D) Negative stain EM of CP-OVA recombinant vaults Bar, 100 nm.
doi:10.1371/journal.pone.0038553.g001
Vaults as Adjuvants for Cellular Immunity
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e38553
This study was performed to characterize the types of immune
responses elicited by engineered vault nanopcapsules compared to
another type of nanocarrier, liposomes, using a well-characterized
model antigen, ovalbumin (OVA). Ovalbumin is a highly
immunogenic antigen and has often been used as a proof of
principle for numerous vaccination strategies [29,30]. We show
that immunization of mice with OVA encapsulated in vault
nanocapsules efficiently stimulates the immune response to elicit
robust CD8+, CD4+ memory T cell responses and antibody titers
to OVA. These data support the use of vault nanocapsules as
subunit vaccines which can generate both cellular and humoral
immunity and provide rationale for using vault nanocapsules to
develop vaccines against antigens for human pathogens and
cancer.
Results
Preparation of Recombinant Vaults Packaged with
Chicken Ovalbumin
Recombinant vaults were produced using a baculovirus
expression system in Sf9 insect cells that express a stabilized form
of recombinant vaults (CP) and contain a cysteine rich peptide on
the N terminus to increase stability [31]. Cryoelectron microscopy
imaging of recombinant and tissue derived vaults revealed the
localization of the MVP interacting domain, INT [31]. Another
form of recombinant vaults (CPZ) contains a 33 amino acid mimic
of the Ig binding domain of staphylococcal protein A (Z) in
addition to the CP peptide [32]. CPZ vaults were shown to bind
antibody and may direct uptake thorough FcRs [27]. These vaults
(CP or CPZ) were packaged with chicken ovalbumin by fusion of
OVA protein to the vault-targeting protein, INT to form OVA-
INT. The OVA-containing vaults were purified and the majority
of particles were found in the 40% and 45% sucrose fraction as
previously described [33]. Analysis of these fractions by SDS-
PAGE and Western blotting (Figure 1) shows the co-purification of
MVP and OVA-INT (Figure 1 A). The identity of the components
was confirmed by Western analysis with either an anti-MVP
polyclonal antibody (Figure 1B) or an anti-OVA antibody
(Figure 1C). Purified CP-OVA recombinant vaults were evaluated
by negative stain electron microscopy (Figure 1D). The addition of
the OVA-INT protein to CP or CPZ did not alter recombinant
vault morphology as compared to empty CP vaults when
evaluated by transmission electron microcopy (data not shown)
and as shown previously [27]. The presence of additional protein
density or lighter staining area (arrow) near the waist of the vault
barrel, which based on earlier structural studies, is the expected
location of OVA-INT [34]. We used these CP and CPZ-vaults
containing OVA-INT in vaccinations, henceforth referred to as
CP-OVA and CPZ-OVA.
Ovalbumin Packaged Inside Vault Nanocapsules can
Induce a MHC-I Restricted Response
Dendritic cells (DCs) possess the unique ability to process
particulate antigens efficiently into the MHC-I pathway, in a
process known as cross-priming. Several approaches have been
used to encourage cross priming such as adding exogenous
antigenic proteins or peptides with adjuvants to stimulate cytotoxic
T lymphocytes (CTLs) [35]. Therefore, we investigated whether
recombinant vaults engineered to express OVA could be
efficiently internalized, processed and presented by DC in an
MHC-I restricted manner to activate CD8+ T cells. To this end,
the DC2.4 cell line (H-2Kb) was pulsed with CP-OVA and
secretion of IL-2 was measured as an activation marker of the
OVA-responsive CD8+ T cell hybridoma B3Z (H-2Kb). The
combination of DC2.4 cells, B3Z cells and CP that did not contain
OVA-INT could not effectively stimulate IL-2 secretion. However,
CP-OVA (produced by combining CP + OVA-INT) incubated
with both DC2.4 cells and B3Z hybridoma cells induced secretion
of IL-2 (Figure 2). We examined different concentrations of CP-
OVA vaults and determined that 3.3 mg CP-OVA vaults per
200 mL per well gave us the greatest IL-2 secretion (data not
shown). Additional controls included the B3Z CD8+ T cell
hybridoma incubated with CP-OVA alone which induced modest
Figure 2. Vault nanocapsules induce cross presentation to CD8 cells. B3Z cells (16105 cells/200 uL/well) were co cultured with DC 2.4
(56104 cells/200 mL/well) in the presence or absence of CP-OVA (3.3 mg/200 uL/well) for 24 hrs. Control vaults (CP) were also used at concentration of
3.3 mg/200 uL/well. Following 24 hrs, T cell activation was analyzed by measuring IL-2 production. Data in all panels are representative of 3
independent experiments. Student’s t-test was used to determine statistical significance between the CP-OVA and control CP-vaults. *p,0.05.
doi:10.1371/journal.pone.0038553.g002
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IL-2 levels and suggests that vaults interact with T cells and
participate in autopresentation of MHC-I responses [36]. Finally,
incubation of CP-OVA vaults with the DC2.4 cell line only
produced baseline levels of IL-2. We concluded that exogenous
antigen packaged within vault nanocapsules could be delivered
and presented by the MHC-I pathway in DCs and possibly
through autopresentation to enhance T cell responses.
Ovalbumin Packaged Inside Vault Nanocapsules can
Induce a MHC-II Restricted Response
We also examined the MHC class II pathway using bone-
marrow–derived DCs from syngeneic BALB/c (H-2 IA/Ed) mice
pulsed with CP-OVA for 24 hours. These DCs were then used to
stimulate naive OVA-responsive CD4+ T cells from DO11.10 (H-
2 A/Ed) mice. D11.10 cells are transgenic for the TCR
recognizing the amino acid 323–339 peptide of OVA on MHC-
II. As shown in Figure 3, DC induced significant proliferation in
the presence of OVA. However, OVA encased in vault
nanoparticles at two concentrations; 2.5 mg and 10.0 mg, stimu-
lated a greater degree of T cell proliferation at both concentrations
compared to recombinant OVA protein alone and were not
statistically different from each other (Figure 3). These data show
that OVA encased in vault nanocapsules was more effective at
inducing CD4+ T cell proliferation than soluble OVA.
Vaccination of Mice with OVA Packaged Vault
Nanocapsules Induces CD8+ and CD4+ T Cells in vivo
We characterized cell- and antibody-mediated immune re-
sponses to OVA encapsulated in vault nanocapsules and liposomes
in vivo following subcutaneous administration. To evaluate the type
of immune response we immunized mice with either CP-OVA or
CPZ-OVA vaults containing equal amounts of endotoxin-free
OVA (see material and methods). Liposomes where chosen as a
control delivery method since they are a class of nanocarriers and
have been utilized as delivery systems for drugs, peptides, proteins
and DNA [29,37]. Liposomes are microscopic vesicles consisting
of phospholipid bilayers which surround aqueous compartments
and were prepared in this study by encapsulating OVA in
DOTAP/DOPE as described in the methods section [38]. The
amount of OVA within the vaults and liposomes was quantitated
by SDS gel quantitation (Figure 4A). Mice were immunized with
equal amounts of delivery vehicle and OVA and the immunization
regimen is described in Figure 4B. The percentage of T cells
responsive to the OVA CD8 peptide (SIINFEKL) or the OVA
CD4 peptide 256–280 (TEWTSSNVMEERKIKV) were docu-
mented by surface, intracellular cytokine or perforin staining and
FACS analysis after stimulation with each OVA peptide in
C57BL/6 mice (H2b background) as described in the methods
section. We also examined the anti-OVA-antibody responses
following immunization by ELISA.
CD8+ T cells play a critical role in protection against viral and
intracellular bacterial and protozoan infections and are important
in tumor and graft rejection [39]. After activation, naive antigen
(Ag)-responsive CD8+ T cells are able to proliferate quickly and
differentiate into potent effector cells capable of rapid cytokine
production and cytolytic killing of target cells [40,41]. We wanted
to see if entrapment of OVA in vault nanocapsules facilitated
cross-presentation of Ag to the MHC-I pathway, resulting in
activation of a potent CD8+ T cell immunity in vivo as we observed
previously in vitro. We evaluated induction of CD8+ T-cell
responses among mice immunized with OVA-vaults (CP-OVA
and CPZ-OVA), empty vaults (CP and CPZ) and Liposome-OVA
as shown in Figure 5. Control groups included soluble OVA and
saline immunization. The induction of effector CD8+ T cell
responses in the spleen was measured 2 weeks after the last
immunization by measuring the number of total CD8+ T cells,
CD8+ memory T cells (CD44hi), expression of the cytolytic marker
perforin, and the production of IFNc and IL-4 after stimulation
with the H2b restricted CD8 OVA peptide, SIINFEKL. All
experimental controls were elevated over their respective controls.
To simplify the graphs we only show statistical results for
Figure 3. Vault nanocapsules induce CD4 T cell activation. T cells (26105 cells/mL) were co-cultured with DC (26104 cells/mL) in the presence
of PBS, recombinant OVA protein (2.5 mg/mL), control CP-vaults and CP-OVA with the indicated concentrations. DC-induced T cell proliferation was
assessed by incorporation of [3H] thymidine. The graphs show mean (SEM) values from a representative experiment (n = 6 replicates) of three
independent experiments. Student’s t test was used to determine the p value by comparing appropriate control. *p,0.05.
doi:10.1371/journal.pone.0038553.g003
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comparison of our control immunization group (Liposome-OVA)
to the other OVA immunization groups. Our ‘‘control’’ group was
Liposome-OVA group because we were interested to learn how
vault immunization differed from liposome immunization.
As shown in Figure 5A, we found a marked in increase of OVA-
responsive SIINFEKL CD8+ T cells in the CPZ-OVA immunized
group over that found in Liposome-OVA immunized mice in the
lymphoid compartment. It was surprising that total CD8+
responses were only slightly elevated in the OVA and CP-OVA
group and suggested that CD8+ T cell subset examination may be
more revealing than examining total CD8+ T cells in the lymphoid
compartment. We also saw an increase in CD8+ memory T cells
(Figure 5B) and CD8+ IFNc producing T cells (Figure 5C) in mice
immunized with OVA encased vault nanocapsules compared to
OVA delivered in liposomes while OVA immunization in saline
did not increase these responses compared to the Liposome-OVA
group. This is consistent with previous studies finding that OVA
alone and liposome delivery does not enhance memory CD8+
cytotoxic T cells [42]. Although we noted an increase in the
number of CD8+ T cells expressing perforin in CPZ-OVA
immunized mice compared to Liposome-OVA immunized mice
we also found increased CD8+ perforin+ T cells in the OVA group
but no increase in the CP-OVA immunized mice. Interestingly,
the number of IL-4 producing cells in CP-OVA immunized mice
had markedly lower numbers compared to other OVA immunized
groups. As expected, vaccination with OVA in any delivery vehicle
or dissolved in saline significantly increased SINFEKL-responsive
CD8+ T cells over control groups for all immunization groups
(Figure 5). These findings demonstrate that immunization of
antigen encased within vaults is cross-presented in vivo and
stimulates a CD8+ T cell response characterized by memory T
cells and IFNc producing T cells.
It has been documented that CD4+ T cell help is important for
CD8+ T cell function. Since we observed increased numbers of
OVA-responsive CD8+ memory and IFNc producing T cells in
CP- and CPZ-OVA immunized mice, we investigated if the
number of CD4+ T cells was also increased following vault
immunization. To address this issue, splenocytes from each group
were stimulated ex vivo with the class II peptide, OVA 265–280 and
the CD4+ T cell response was characterized by FACS.
We found that immunization with CPZ-OVA but not CP-OVA
vault nanocapsules induced a significant amount of total CD4+ T
cells in the lymphoid compartment of the spleen when compared
to Liposome-OVA group (Figure 6A). Also, immunization with
both forms of vault nanocapsules significantly elevated the number
of CD4+ memory T cells compared to Liposome-OVA immunized
mice (Figure 6B). We did not see a significant increase in IFNc or
IL-17 producing CD4+ T cells over that seen in Liposome-OVA
immunized mice following vault or liposome immunization of
OVA (Figures 6C & D). However, CPZ-OVA but not CP-OVA
immunization induced similar numbers of IL-4 producing CD4+
T cells as mice immunized with Liposome-OVA (Figure 6E). We
also noted significant increases in subsets as well as total CD4+ T
cells in all immunized groups when compared to control groups as
expected (Figure 6). Taken together, these data show that
immunization with CPZ-OVA induces CD4+ T cells character-
ized by memory cells and IL-4 producing cells. Immunization with
CPZ vaults results in the combination CD8+ T cells and CD4+
helper T cells.
Vault Nanocapsules can be Modified to Induce Select
Antibody Ig Isotypes
Co-operation of CD4+ T helper cells with antigen specific B
cells is crucial for inducing long-lived neutralizing antibody
responses for protective immunity followed by vaccination [43].
We investigated whether OVA delivered in vault nanocapsules
also induced anti-OVA antibody since they were capable of
inducing CD4+ T cell memory and IL-4 producing cells. The
serum titers of OVA-responsive IgG1 and IgG2c in each group
were measured after immunization by ELISA. We found that mice
immunized with Liposome-OVA induced significantly greater
levels of anti-OVA IgG1 and IgG2c compared to CP-OVA, CPZ-
OVA or OVA immunized mice (Figures 7A & B) indicating that
liposomes induce high levels of anti-OVA antibody [44–46].
Further inspection revealed that the addition of the ‘‘Z’’ domain
reduced mean anti-OVA IgG2c titers by 0.5 to 1 log in
comparison to CP-OVA and OVA groups while IgG1 remained
comparable. Comparison of the ratio of anti-OVA IgG1:IgG2c
revealed that Liposome-OVA immunized mice produced equal
levels of IgG1 and IgG2c resulting in a ratio near one while
immunization with CP-OVA, CPZ-OVA or OVA increased the
ratio of IgG1:IgG2. Moreover, mice immunized with vault
nanocapsules modified to express the ‘‘Z’’ domain (CPZ-OVA)
had a significantly increased this ratio compared to Liposome-
OVA immunized group. In contrast, the OVA and CP-OVA
groups were not significantly different compared to the Liposome-
OVA group (Figure 7C). As expected all OVA immunization
groups induced significant IgG1 and IgG2c serum antibody titers
compared to the corresponding controls (Figure 7). These data
show that modification of the vault body by addition of the ‘‘Z’’
domain modifies the antibody isotype and suggests that the vault
nanocapsule can be modified to alter the humoral responses.
Discussion
The work presented here illustrates the potential of engineered
vault nanocapsules to act as potent adjuvants for the induction of
combined cellular and humoral immune responses. Overall, our
results demonstrate that immunization of OVA encased in vault
nanocapsules, was more effective at generating greater cellular
immunity characterized by increased numbers of OVA responsive
memory CD8+ and CD4+ T cells. Also, modification of the vault
body, by addition of the ‘‘Z’’ domain, altered the level of anti-
OVA Ig subclass as shown by an increased IgG1:IgG2C ratio.
These findings show that immune responses against OVA induced
by vault nanoparticles differ compared to those induced by
liposomes.
An important feature of vault nanocapsules as adjuvants is the
robust induction of CD8+ and CD4+ memory T cells. The delivery
of antigens to antigen presenting cells, especially DC, is a critical
step for initiating and regulating the adaptive immune responses
and we have shown that DC efficiently internalize vault
nanocapules [27,41]. We have also shown that vaults containing
immunogenic proteins activate inflammasomes and escape into
Figure 4. Quantitation of OVA in delivery vehicles and immunization regimen. (A) Images of representative 4–15% SDS polyacrylamide gel
showing standards, CP-OVA, CPZ-OVA and OVA-liposomes. The amount of OVA incorporated into the delivery vehicles were quantitated using a
Typhoon 9410 Typhoon Variable Mode Scanner of Coomassie blue stained SDS-PAGE gels. (B) Schematic representation of vaccination schedules and
subcutaneous immunizations with saline (#), unencapsulated OVA with saline (&), CP (m), CP-OVA (m), CPZ (X), CPZ-OVA (X), liposome (N), or
liposome-OVA (N). The immunization regimen involved three vaccinations (day -28, -14 and 0).
doi:10.1371/journal.pone.0038553.g004
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the cytoplasm [unpublished data, [27]. This may explain induction
of an OVA-responsive CD8+ memory T cell response and cross-
presentation. Vaults may also stimulate antigen-responsive CD8+
and CD4+ memory T cells by acting as intracellular depots or
altering JAK/STAT signaling [47].
A potential vaccine should have the ability to induce and
maintain antigen-responsive effector and/or memory T cells [7].
Our data show that immunization with vault nanocapsules was
capable of inducing phenotypic markers of memory cells in CD8+
and CD4+ T cells. It will be interesting to extend these studies and
examine memory responses in vivo using protection from infection
or tumor models. In addition, we found enhanced production of
OVA-responsive CD8+ T cells that could secrete IFNc. Surpris-
ingly, there was not much difference between Liposome-OVA and
OVA immunized groups and one questions the present of LPS.
We did not measure LPS concentrations directly but all reagents
used were endotoxin free and the purchased OVA was endotoxin
free (see methods). However, there are differences in the amount of
IFNc produced when splenocytes are stimulated with OVA
protein, CD8 or CD4 OVA peptides and whether IFNc is
measured in total splenocytes or CD8+ or CD4+ T cells [48].
The induction of effector CD4+ T cells occurs in the same
manner and with similar dynamics as is seen with the induction of
effector memory CD8+ T cells [43]. However, the increased CD4+
memory T cells appear to be dominated by helper cells in mice
immunized with CPZ-OVA vaults. Our data shows that the
addition of the ‘‘Z’’ domain modifies antibody isotypes and
supports the increased ratio of anti-OVA IgG1 over IgG2c titers.
Adjuvants enhance immunity to immunogens but also steer
immunity toward specific immune responses. For instance, alum is
a known to promote Th2 responses [49]. The ability of vault
vaccines to alter antibody isotypes suggests that modification of the
vault toward certain immune responses is possible [50]. Recently,
we have modified the vault by the addition of a lytic peptide
derived from the adenovirus pIV protein. This modification allows
those vaults to rapidly escape phagocytic vesicles [51]. Future
studies will examine the in vivo immune responses generated by
these vaults.
These results plus our previous studies with chemokines
(CCL21) [28] and a chlamydial protein (MOMP) [27], supports
the hypothesis that vault nanocapsules can be potent antigen
delivery vehicles. Vault nanocapsules act as ‘‘smart’’ adjuvants that
are capable of directing immunity toward desired responses with
little induction of inflammatory cytokines when delivered via a
mucosal route [27]. Further studies comparing immunization
routes will be needed to determine the most effective route for the
desired immune response. Since vaults are ubiquitous and
conserved across eukaryote species, the platform has a major
advantage over other delivery systems which have safety concerns
associated with attenuated bacteria or viruses. In addition, vault
nanocapsules are uniform in size and are able to be produced in
abundance. Combining adjuvant and carrier activity, engineered
vaults enhance the response with a much lower dose of the antigen
and circumvent the protein-purification requirements of tradition-
al subunit vaccines and particulate antigen-delivery modalities.
With possibilities of further engineering the surface of vaults to
either target specific cells or by allowing the proteins to escape
endosomes, vaults provide a uniquely tunable platform with ease
of manufacture for the delivery of a wide spectrum of subunit
antigens for vaccines against infectious disease or other therapeutic
targets.
Materials and Methods
Ethics Statement
All animal Experimental procedures were approved by the
UCLA Institutional Animal Care and Use Committee and
conducted according to relevant national and international
guidelines. All procedures are designed to provide for maximum
comfort/minimal stress to the animals and cannot be further
refined to minimize pain/distress since there are no less painful/
distressful options available. The procedures are presently refined
to provide the best possible scientific methodologies available. The
animals are monitored for signs of agitation (licking, biting or
guarding the vaginal region), failure to groom, loss of appetite, or
marked weight loss (.10%), we will notify the Attending
Veterinarian for his/her recommendation for a prophylactic
treatment.
Expression and Purification of Recombinant Vaults
Recombinant baculoviruses were generated using the Bac-to-
Bac protocol (Invitrogen, Carlsbad, CA). The 385 amino acid
coding region of ovalbumin was fused to major vault protein
interaction domain (INT) derived from VPARP (amino acids
1563–1724) by PCR ligation [52,53]. Two PCR reactions were
carried out: OVA-forward :CCCCACTAGTCCATGGGCTC-
CATCGG and OVA-INT reverse:
TCCTGCCAGTGTTGTGTGCAGCTAGCAGGGGAAACA-
CATCTGCC using plasmid pMFG-OVA as the template
(plasmid pMFG-OVA was a kind gift from Dr Carlo Heirman,
Laboratory of Molecular and Cellular Therapy, Department of
Physiology–Immunology, Medical School of the Vrije Universiteit
Brussel, Brussels, Belgium). The second PCR reaction with primer
OVA-INT forward: TTGGCAGATGTGTTTCCCCTGC-
TAGCTGC ACACAACACTGGCAGGA and INT reverse:
GGGCTCGAGTTAGCCTTGACTGTAATGGAG using INT
in pET28 as the template. The PCR reactions were purified on a
Qiagen column and a second round of PCR was carried out using
the OVA-forward 6 INT reverse. The resultant PCR product
containing the fused OVA-INT was purified on a Qiagen column,
digested with Spe I and Xho I, gel purified, and ligated to
pFastBac to form a pFastBac vector containing OVA-INT.
Construction of cp-MVP-z, or cp-MVP in pFastBac has been
described previously [32].
Sf9 cells were infected with Ova-INT, cp-MVP-z, or cp-MVP
recombinant baculoviruses at a multiplicity of infection (MOI) of
0.01 for approximately 65 h and then pelleted and lysed on ice in
buffer A [50 mM Tris-HCl (pH 7.4), 75 mM NaCl, and 0.5 mM
MgCl2] with 1% Triton X-100, 1 mM dithiothreitol, 0.5 mM` mg/
ml chymostatin, 5 mM leupeptin, 5 mM pepstatin) (Sigma, St.
Louis, MO). Lysates containing cp-MVP-z vaults were mixed with
lysates containing either OVA-INT were incubated on ice for
Figure 5. Vault nanocapsules enhance priming of endogenous CD8+ T cells. Mice were injected with various immunogens as shown on the
x-axis; saline (#), unencapsulated OVA with saline (&), CP (m), CP-OVA (m), CPZ (X), CPZ-OVA (X), liposome (N), or liposome-OVA (N). Splenocytes
were harvested, stained and gated on lymphocytes as described in the methods section. The frequency of CD8 subpopulations are shown on the y-
axis. (A) Total CD8+ cells, (B) CD8+ memory cells (CD8+CD44hi), (C) IFNc-producing CD8+ cells, (D) Perforin-expressing CD8+ cells and (E) IL-4
producing CD8 cells. The cell populations from immunized groups were compared using one-way ANOVA and Bonferroni’s post-hoc test).
***p,0.001, **p,0.01, *p,0.05. Representative of 3 independent experiments.
doi:10.1371/journal.pone.0038553.g005
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30 min to allow the INT fusion proteins to package inside of
vaults. Recombinant vaults were purified as previously described
[33] and resuspended in 100–200 ml of sterile phosphate buffered
saline. The protein concentration was determined using the BCA
assay (Pierce, Rockville, IL) and sample integrity was analyzed by
negative stain electron microscopy and SDS-PAGE with Coo-
massie staining or transferred to hybond membrane (Amersham)
for Western blot analysis. The density of the bands was determined
by gel scanning and densitometry analysis using a 9410 Typhoon
Variable Mode Scanner (GE Healthcare Life Sciences, Piscat-
away, NJ).
Preparation of OVA-liposomes
To generate OVA-liposomes, 10 mg lyophilized DOTAP/
DOPE (1:1) (1,2-dioleoyl-3-trimethylammonium-propane/1,2-
dioleoyl-sn-glycero-3-phospho-ethanolamine) (Avanti Polar Lipids,
Alabaster, AL) was re-hydrated in 1 mL endotoxin-free 5%
glucose and mixed slowly (rotated) overnight at room temperature.
Lyophilized EndoGrade Ovalbumin (,1 EU/mg i.e. 1 endotoxin
unit has ,0.1 ng of endotoxin) (Profos AG, BioVender, LLC,
Candler, NC) was reconstituted in endotoxin-free sterile saline
(,0.1 EU/mL endotoxin, Sigma) to a stock solution of 10 mg/
mL. Aliquots were stored frozen and thawed immediately before
use. The entrapment of OVA was generated by combining
1.25 mg of resuspended ovalbumin with 2.5 mg of swollen
DOTAP/DOPE lipids and further facilitated by brief sonication.
OVA-liposomes were separated from unincorporated ovalbumin
by ultracentrifugation at 100,0006g using an Optima XL-80K
(Beckman Coulter, Fullerton, CA) ultracentrifuge and washed two
additional times. Quantitation of encapsulated OVA was deter-
mined by subjecting OVA-liposomes (1, 2, 4 mL) to SDS-PAGE
electrophoresis in parallel with known amounts of ovalbumin
(0.25, 0.5, 1.0, 2.5, 5 mg) and visualized by Coomassie blue
staining.
Gel Electrophoresis and Immunoblotting
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was
performed using the discontinuous buffer system and 4–15%
acrylamide gels. Protein samples of OVA-liposome or OVA-vaults
were transferred to an Immobilon-P transfer membrane (Milli-
pore, city, Bedford, MA) and blocked with 5% nonfat dry milk in
PBS-0.1% Tween 20 (PBS-T). Membranes were incubated for
1 hr with anti-MVP (1:500, MAB 1023, Santa Cruz Biotechnol-
ogy Inc, Santa Cruz, CA) or anti-INT followed by a 1 h
incubation with the appropriate horseradish conjugate (1:5,000,
Amersham Biosciences, Piscataway, NJ). Bound conjugates were
detected with ECL-Plus (GE Healthcare, Life Sciences, Piscat-
away, NJ) and 9410 Typhoon Variable Mode Scanner (GE
Healthcare Life Sciences, Piscataway, NJ).
Antigen Processing and Presentation Assay
DC2.4 H-2Kb (56104/well) were plated in triplicates in 96-well
plates and allowed to settle at 37uC. Then, MHC Class I restricted
CD8+ T cell line B3Z (105/well) were added, in the presence of
control vaults (200 ng/mL) and OVA vaults (200 ng/mL) for
24 hrs. After 24 h incubation at 37uC, the plate was centrifuged at
1800 rpm, and the culture supernatant was collected and assayed
for IL-2 using an IL-2 ELISA kit (BD Biosciences, San Jose, CA).
DC-dependent T Cell Proliferation
DC cultures were generated by flushing the bone marrow (BM)
from the bone shafts, washed and plated bacteriological Petri
dishes (Falcon Plastics, Oxnard, CA). The cells were cultured at
26105 cells/mL in RPMI 1640 culture medium (10 mM HEPES/
2 mM l-glutamine/10% 0.22 um filtered FBS/50 uM b-mercap-
toethanol) supplemented with mGM-CSF (20 ng/mL) and mIL-4
(20 ng/mL) in an atmosphere of 5% CO2 at 37uC. Fresh medium
containing mGM-CSF (20 ng/mL) and mIL-4 (20 ng/mL) was
added for 3–6 days after the start of culture. To induce
maturation, cells were cultured for an additional 24 h in the
presence of LPS (1 mg/mL). The DC were harvested and purified
with anti-CD11c magnetic beads, and suspended in complete
RPMI-1640 medium and seeded at 56105/mL/well on 24-well
culture plates followed by incubation with 25 and 100 mg/mL of
CP-OVA or recombinant OVA protein for 4 h at 37uC, 5% CO2.
Nonadherent cells consisting of mostly immature or mature DC
were harvested for all the analyses performed in this study.
Responder CD4+ T cells were separated from splenocytes with
mouse CD4+ T-cell enrichment system (StemCell Technologies,
Vancouver, Canada) according to the manufacturer’s instructions.
CD4+ T cells (26104/well) were added to OVA protein or CP-
OVA pulsed DC and cultured for an additional 4 days. During the
last 16–18 h of the 4-day culture, cells were pulsed with 1 mCi
[3H]thymidine (Amersham, Arlington, IL). The cells were
harvested onto filter paper and [3H]thymidine incorporation
was measured with a b-plate scintillation counter (PerkinElmer,
Wellesley, MA).
Immunization Procedures
The OVA protein concentration was adjusted using endotoxin-
free sterile saline (,0.1 EU/mL, 1 EU has ,0.1 of endotoxin
(Sigma) to 2.5 mg OVA in 20 mg of vault nanoparticles or
liposomes using a Typhoon 9410 Variable Mode Scanner of
Coomassie blue stained SDS-PAGE gels. The immunogens were
injected into C57BL/6 mice (5–6 wk old) by subcutaneous
injections at the base of the neck in 100 ml sterile saline. The
mice were immunized 3 times at 2 wk intervals. The spleen and
blood was obtained 2 wk after the last immunization. The
splenocytes were immediately used for FACS analysis and serum
samples were stored frozen at 280uC until assayed.
Measurement of anti-OVA Antibody from Serum
An ELISA was used to determine the level of anti-OVA
antibody isotypes in the serum. Briefly 96-well microtitre plates
(Nunc, Roskilde, Denmark) were coated with 75 ml per well of
OVA (1 mg/75 ml) in PBS and incubated over night at 4uC. After
being washed in buffer (phosphate buffered saline containing
0.05% Tween-20 (v/v) (PBS/T20) the plates were blocked with
150 ml of PBS supplemented with 5% non-fat dry milk for 2 h at
room temperature. After washing, 7 ml of serum diluted from 1:40
to 1:5120 in PBS was added and incubated at 4uC overnight.
Unbound antibody was then washed away and 75 ml of goat anti-
Figure 6. Vault nanocapsules encourage production of CD4+ T cells upon vaccination. Mice were injected with various immunogens as
shown on the x-axis; saline (#), unencapsulated OVA with saline (&), CP (m), CP-OVA (m), CPZ (X), CPZ-OVA (X), liposome (N), or liposome-OVA
(N). Splenocytes were harvested, stained and gated on lymphocytes as described in the methods section. The frequency of CD4 subpopulations are
shown on the y-axis. (A) Total CD4+ cells, (B) CD4+ memory cells (CD4+CD44hi), (C) IFNc-producing CD4+ cells, (D) IL-17 producing CD4+ cells and (E)
IL-4 producing CD4 cells. The cell populations from immunized groups were compared using one-way ANOVA and Bonferroni’s post-hoc test).
***p,0.001, **p,0.01, *p,0.05. Representative of 2 independent experiments.
doi:10.1371/journal.pone.0038553.g006
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mouse IgG1- IgG2c-biotin (Southern Biotechnology Associates,
Inc., Birmingham, AL), diluted 1/10,000 in PBS, was added and
the plates incubated for 4 h at room temperature. The plates were
then washed and 75 ml of NeutraAvidin horse radish peroxidase
diluted in PBS at 1:1000 was added for 20 min. After a final wash
step, 100 mL of TetraMethylBenzidine (TMB) (Zymed Laborato-
ries Inc., San Francisco, CA) substrate was added and incubated at
room temperature, in the dark, for 20 min. The reaction was
stopped with 50 mL of 2 N sulphuric acid and the plates were read
at 450 nm in a microplate reader (Model 550, Bio-Rad
Laboratories, Hercules, CA).
Measurement of IL-2 Production
Spleens were removed and placed in RPMI media (Gibco,
Grand Island, NY) supplemented with 10% heat inactivated FCS.
They were macerated to release the lymphocytes which were then
washed by centrifugation. The cell pellet was resuspended in fresh
media at a concentration of 26106 cells/mL and 1 mL of cells
placed in each well of a 24-well plate (Nunc, Roskilde, Demark).
They were restimulated with media (negative control) or OVA
(100 mg/mL) for 72 h at 37uC in a humidified atmosphere with
5% CO2. The plate was frozen until required. One hundred
microlitres of the supernatants were tested for IL-2 in a sandwich
ELISA following the manufacturer’s instructions (PharMingen,
San Diego, USA). In brief, 96-well, flat-bottomed plates were
coated with 50 mL of a 2 mg/mL concentration of capture
antibody (PharMingen). Plates were washed and blocked with
200 mL/well of PBS/FCS. Doubling dilutions of standards and
supernatants were added and incubated at 4uC overnight. The
plates were washed and 100 mL of a biotin-conjugated detecting
mAb (PharMingen) was added at a concentration of 1 mg/mL.
The enzyme and substrate were then added and analyzed as per
the serum antibody ELISA. The amount of each cytokine in the
supernatant was extrapolated from the standard curve derived
using recombinant IL-2 (PharMingen) standards.
Characterization of T Cell Populations by Flow Cytometry
Lymphocytes were isolated from spleens by mechanical
disruption through a cell strainer. RBCs were lysed using
ammonium chloride-potassium buffer. The cells were stimulated
at 37uC with OVA peptide 265–280:TEWTSSNVMEERKIKV
(2 mg) to identify CD4 cells or OVA peptide: SIINFEKL (2 mg) to
identify CD8 cells for 5 hr. For the last 4 h, cells were incubated in
the presence of Brefeldin A (BioLegend) at 1 mg/mL. At the end of
culture, the cells were stained using fluorochrome-conjugated
MAbs against CD3, CD8, CD4, CD44, CCR7 and CD62L
(BioLegend, San Diego, CA) in staining buffer (PBS with 2% fetal
bovine serum and 0.1% sodium azide) and then treated with Fix/
Perm (BioLegend). After permeabilization, the cells were further
stained with fluorochrome-conjugated antibodies against IFN-c,
IL-4, IL-17 and perforin. Data were collected on LSR II (BD
Biosciences, San Jose, CA) and analyzed using FCS Express (De
Novo Software, Los Angeles, CA). CD8+ and CD4+ T cells were
determined by gating on lymphocytes (FSC vs SSC) and CD8+ or
Figure 7. Vault nanocapsules produce lower anti-OVA anti-
body titers. Antibody titers after vaccination schedule, composed of 3
weekly s.c. injections with control saline (N), unencapsulated OVA in
saline (&), CP-OVA (m), CPZ-OVA (X) or Liposome-OVA (N). (A) Total
anti-OVA-IgG1 titers and (B) Total anti-OVA-IgG2c titers. Significance
was determined by ANOVA (p,0.001) with Bonferroni post-hoc test
(***p,0.001). (C) Ratio of anti-OVA IgG1 to IgG2c antibody. The ratio of
Liposome-OVA immunized mice were compared to the other OVA-
immunized groups using Mann Whitney t-test (*p,0.001). Data are
representative of 2 independent experiments.
doi:10.1371/journal.pone.0038553.g007
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CD4+ memory, cytokine producing or perforin expressing T cells
were determined by gating on either CD3+CD8+ or CD3+CD4+ T
cells as shown in Figure S1.
Statistical Analysis
Statistical analysis was performed using Prism 5 (GraphPad, San
Diego, CA). Data are presented as mean for each group and
statistical significance for IL-2 secretion, proliferation, flow
cytometry and Ig titers were determined by one way analysis of
variance (ANOVA) with Bonferroni’s Multiple Comparison Test.
The ratio of isotypes was compared by Kruskal-Walis and Dunn’s
post-test.
Supporting Information
Figure S1 Flow cytometry gating scheme used to define
cell populations. (A) A representative dotplot from a CPZ-OVA
immunized mouse was gated on lymphocytes using SSC versus
FSC. The percent of CD3+CD8+ memory T cells was determined
from the events in the lymphocyte gate. (B) The lymphocyte gated
population was further gated on CD3+ T cells and CD3+ T cells
were separated into CD8+ or CD4+ T cells. Memory cell
population was determined by hi expression of CD44 and a gate
drawn. This was applied to all experimental mice to determine the
percentage of CD8+ memory cells. The scheme was applied to
CD8+ or CD4+ T cells producing cytokines or expressing perforin
by gating on the CD3+CD8+ or CD3+CD4+ population.
(TIF)
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